Li Xiaohui, Li Mengfei, Chen Dong, Shi Gongning, Zhao Hui
Department of Cardiothoracic Surgery, Huaihe Hospital of Henan University, Kaifeng, China.
Arch Med Sci. 2018 Oct;14(6):1289-1297. doi: 10.5114/aoms.2017.72220. Epub 2017 Dec 13.
Lung cancer is the leading cause of cancer-related death worldwide and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. PAQR (progestin and adipoQ receptor family) 3, a Golgi-anchored membrane protein, has been demonstrated to act as a tumor suppressor in multiple cancers. However, the expression and role of PAQR3 have never been explored in NSCLC. The purpose of this study was to investigate the expression and role of PAQR3 in NSCLC.
Expression of PAQR3 at mRNA and protein levels was determined by qRT-PCR and western blot, respectively. Cell proliferation was analyzed by MTT assay. Apoptosis and cell cycle distribution were evaluated by flow cytometry.
The expression of PAQR3 was downregulated in NSCLC tissue samples and cell lines at both mRNA and protein levels ( < 0.05). Overexpression of PAQR3 significantly inhibited cell proliferation, induced apoptosis and promoted cell cycle arrest at G0/G1 phase in NSCLC cell lines ( < 0.05). In contrast, knockdown of PAQR3 showed a reverse effect on NSCLC cells ( < 0.05). Moreover, PAQR3 may exert its tumor suppressive roles via suppressing the PI3K/AKT signaling pathway in NSCLC.
Our findings suggest that PAQR3 is a tumor suppressor in the development of NSCLC and may serve as a novel therapeutic target in the treatment of patients with NSCLC.
肺癌是全球癌症相关死亡的主要原因,非小细胞肺癌(NSCLC)约占所有肺癌病例的85%。PAQR(孕激素和脂肪Q受体家族)3是一种锚定在高尔基体的膜蛋白,已被证明在多种癌症中发挥肿瘤抑制作用。然而,PAQR3在NSCLC中的表达和作用从未被探讨过。本研究的目的是调查PAQR3在NSCLC中的表达和作用。
分别通过qRT-PCR和蛋白质印迹法测定PAQR3在mRNA和蛋白质水平的表达。通过MTT法分析细胞增殖。通过流式细胞术评估细胞凋亡和细胞周期分布。
在NSCLC组织样本和细胞系中,PAQR3在mRNA和蛋白质水平的表达均下调(<0.05)。PAQR3的过表达显著抑制NSCLC细胞系中的细胞增殖、诱导细胞凋亡并促进细胞周期停滞在G0/G1期(<0.05)。相反,敲低PAQR3对NSCLC细胞显示出相反的作用(<0.05)。此外,PAQR3可能通过抑制NSCLC中的PI3K/AKT信号通路发挥其肿瘤抑制作用。
我们的研究结果表明,PAQR3是NSCLC发生发展中的一种肿瘤抑制因子,可能作为NSCLC患者治疗的新靶点。